Ian McNiece

Ian McNiece

Company: Oncocyclist & BioCardia & Aegle Therapeutics

Job title: Chief Executive Officer & Chief Scientific Officer & Vice President, Research & Development


Ian McNiece Ph.D. Dr McNiece received his Ph.D. in physiology in 1986 from the University of Melbourne, he moved to the US in 1986 as a postdoctoral fellow at the University of Virginia, Charlottesville, Virginia. He was Laboratory Head in the Department of Developmental Hematology at Amgen Inc where he was involved in product development of Filgrastim, Neulasta, Stemgen, and led development of cellular therapies. He returned to academia as Professor of Medicine at the University of Colorado Health Science Center (1997-2002), Johns Hopkins University (2003-2007), the University of Miami (2007-2012) and MD Anderson Cancer Center (2012-2016). He is currently CEO and CSO of Oncocyclist Inc, which is developing immune therapies against cancer utilizing cellular products and cellular derived products.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.